Solid lipid nanoparticles for hydrophilic drugs

Mirchandani, Yashika; Patravale, Vandana; Brijesh, S

doi:10.1016/j.jconrel.2021.05.032

Cited by 126 publications

(74 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As drug nanocarriers, SLNs enable the encapsulation of hydrophobic and hydrophilic drugs (a detailed review on the hydrophilic drug encapsulation can be consulted in [ 142 ]) through three potentially distinct manners [ 76 , 138 ]. These can be: (i) dispersed homogeneously in the lipid matrix, (ii) dispersed throughout the shell (surfactant layer), and (iii) incorporated in the core ( Figure 6 ).…”

Section: Solid Lipid Nanoparticlesmentioning

confidence: 99%

Magnetic Solid Nanoparticles and Their Counterparts: Recent Advances towards Cancer Theranostics

et al. 2022

View full text Add to dashboard Cite

Cancer is currently a leading cause of death worldwide. The World Health Organization estimates an increase of 60% in the global cancer incidence in the next two decades. The inefficiency of the currently available therapies has prompted an urgent effort to develop new strategies that enable early diagnosis and improve response to treatment. Nanomedicine formulations can improve the pharmacokinetics and pharmacodynamics of conventional therapies and result in optimized cancer treatments. In particular, theranostic formulations aim at addressing the high heterogeneity of tumors and metastases by integrating imaging properties that enable a non-invasive and quantitative assessment of tumor targeting efficiency, drug delivery, and eventually the monitoring of the response to treatment. However, in order to exploit their full potential, the promising results observed in preclinical stages need to achieve clinical translation. Despite the significant number of available functionalization strategies, targeting efficiency is currently one of the major limitations of advanced nanomedicines in the oncology area, highlighting the need for more efficient nanoformulation designs that provide them with selectivity for precise cancer types and tumoral tissue. Under this current need, this review provides an overview of the strategies currently applied in the cancer theranostics field using magnetic nanoparticles (MNPs) and solid lipid nanoparticles (SLNs), where both nanocarriers have recently entered the clinical trials stage. The integration of these formulations into magnetic solid lipid nanoparticles—with different composition and phenotypic activity—constitutes a new generation of theranostic nanomedicines with great potential for the selective, controlled, and safe delivery of chemotherapy.

show abstract

Section: Solid Lipid Nanoparticlesmentioning

confidence: 99%

Magnetic Solid Nanoparticles and Their Counterparts: Recent Advances towards Cancer Theranostics

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The past decade has witnessed tremendous advances in the field of nanoparticle engineering technologies. Recently, nanotechnology-based drug delivery systems such as nanoparticles ( 67 ), polymer micelles ( 68 , 69 ), polymer vesicles ( 70 ), dendrimer ( 71 ), liposomes ( 72 ), SLN ( 73 ), NLC ( 74 ) and nanoemulsion ( 75 ) have been demonstrated to be excellent platforms for drug delivery to address the oral delivery challenges. Among them, liposomes most commonly was used in nanoformulation for drug delivery of a wide range ( 76 ).…”

Section: Application Of Nanocarrier In the Delivery Of Pharmaceuticalsmentioning

confidence: 99%

A Review on Polymer and Lipid-Based Nanocarriers and Its Application to Nano-Pharmaceutical and Food-Based Systems

Zhang

Wang

et al. 2021

Front. Nutr.

View full text Add to dashboard Cite

Recently, owing to well-controlled release, enhanced distribution and increased permeability, nanocarriers used for alternative drug and food-delivery strategies have received increasingly attentions. Nanocarriers have attracted a large amount of interest as potential carriers of various bioactive molecules for multiple applications. Drug and food-based delivery via polymeric-based nanocarriers and lipid-based nanocarriers has been widely investigated. Nanocarriers, especially liposomes, are more and more widely used in the area of novel nano-pharmaceutical or food-based design. Herein, we aimed to discuss the recent advancement of different surface-engineered nanocarriers type, along with cutting-edge applications for food and nanomedicine and highlight the alternative of phytochemical as nanocarrier. Additionally, safety concern of nanocarriers was also highlighted.

show abstract

“…Nowadays, colloidal drug delivery systems have enhanced the oral pharmacokinetic characteristics of therapeutic agents and their bioavailability [20,21]. In early 1990s, solid lipid nanoparticles (SLNs), colloidal drug delivery systems, were introduced.…”

mentioning

confidence: 99%

“…In early 1990s, solid lipid nanoparticles (SLNs), colloidal drug delivery systems, were introduced. They range from 30 to 1,000 nm in size and are prepared from solid lipids and stabilized by surfactants [20][21][22]. SLNs have received more attention than other nano-delivery systems oral administration including controlled drug release by the hindrance of solid lipid shells, enhanced absorption through the lymphatic delivery through microfold cells, and extensive drug payload characteristics based on loaded both lipophilic and hydrophilic drugs [20][21][22].…”

mentioning

confidence: 99%

“…They range from 30 to 1,000 nm in size and are prepared from solid lipids and stabilized by surfactants [20][21][22]. SLNs have received more attention than other nano-delivery systems oral administration including controlled drug release by the hindrance of solid lipid shells, enhanced absorption through the lymphatic delivery through microfold cells, and extensive drug payload characteristics based on loaded both lipophilic and hydrophilic drugs [20][21][22]. The conventional SLNs are associated with various advantages, however, intragastric administration of bioactive compounds is challenging, that is, burst release of compounds in the stomach at a pH of approximately 1 ~ 3, which is low [23][24][25][26].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Chitosan derivatives modified solid lipid nanoparticles prolonged Rhodojaponin-III active time and enhanced the safety and multimodal analgesic effects in vivo

Yang

Sun

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Rhodojaponin III (RJ-III), a bioactive diterpene, is a characteristic component of Rhododendron molle G. Don (Ericaceae), a potent analgesia in traditional Chinese medicine with thousands of years of clinical applications. However, its clinical use is limited by its acute toxicity and poor pharmacokinetic profile. To reduce such limitations, we incorporated RJ-III into the colloidal drug delivery system of hydroxypropyl trimethyl ammonium chloride chitosan (HACC) modified solid lipid nanoparticles (SLNs) to improve its sustained release and analgesic properties in vivo for oral delivery. Results The optimized RJ-III@HACC-SLNs were close to spherical, approximately 134 nm in size, with a positive zeta potential. In vitro experiments showed that RJ-III@HACC-SLNs were stable in the simulated gastric fluid, and were prolonged release in PBS (pH = 6.8). Pharmacokinetics results showed that after intragastric administration in mice, the relative bioavailability of RJ-III@HACC-SLNs was 87.9%, the peak time, half-time, and mean retention time of RJ-III@HACC-SLNs were significantly improved. Pharmacodynamic studies revealed that RJ-III@HACC-SLNs markedly reduced the acetic acid, hot, and formalin-induced nociceptive responses in mice (P < 0.001), and significantly increased the analgesic time (P < 0.01). Moreover, RJ-III@HACC-SLNs not only showed good biocompatibility with Caco-2 cells in vitro, but its LD50 value was also increased by 1.8-fold compared to RJ-III in vivo. Conclusions This study indicated that RJ-III@HACC-SLNs could exhibit certain toxicity-attenuating and effectiveness-enhancing effects by improving pharmacokinetic characteristics of the RJ-III, which could be a new strategy for intragastric delivery and analgesic treatment of RJ-III and HACC-modified SLNs, and provide a dosage form reference for the further study of RJ-III.

show abstract

Solid lipid nanoparticles for hydrophilic drugs

Cited by 126 publications

References 60 publications

Magnetic Solid Nanoparticles and Their Counterparts: Recent Advances towards Cancer Theranostics

Magnetic Solid Nanoparticles and Their Counterparts: Recent Advances towards Cancer Theranostics

A Review on Polymer and Lipid-Based Nanocarriers and Its Application to Nano-Pharmaceutical and Food-Based Systems

Chitosan derivatives modified solid lipid nanoparticles prolonged Rhodojaponin-III active time and enhanced the safety and multimodal analgesic effects in vivo

Contact Info

Product

Resources

About